©
Shutterstock
The UK Cystic Fibrosis Gene Therapy Consortium, of which the University is a member, will join with Boehringer Ingelheim and Oxford Biomedica to develop a new viral vector-based therapy.
The partnership builds on pioneering research carried out by the Consortium including clinical trials, which have shown encouraging results.